TMO

Thermo Fisher Scientific Inc. operates in the Health Care sector, within the Life Sciences Tools and Services industry. Formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International, the company combines analytical instrumentation, laboratory equipment, and scientific distribution capabilities.

Thermo Fisher develops and supplies technologies used across biomedical research, pharmaceutical development, clinical diagnostics, and biomanufacturing.

Its portfolio includes:

• Analytical instruments such as spectrometers and electron microscopes.

• Genomic sequencing and PCR systems.

• Cell culture and bioprocessing technologies.

• Laboratory reagents and consumables.

• Molecular diagnostics platforms.

• Contract development and manufacturing services (CDMO).

The company serves pharmaceutical and biotechnology firms, hospitals, academic institutions, research laboratories, and government agencies worldwide.

Thermo Fisher operates in more than 50 countries, supported by manufacturing sites, research centers, regulated production facilities, and global distribution networks.

Performance is influenced by biotechnology innovation cycles, pharmaceutical R&D spending, regulatory standards, laboratory infrastructure investment, demand for molecular diagnostics, and expansion of personalized medicine.

Thermo Fisher shares trade on the New York Stock Exchange (NYSE) under the ticker TMO.

History and Development

Thermo Fisher’s origins stem from two separate companies. Thermo Electron, founded in the mid-20th century, specialized in analytical instruments and engineering technologies. Fisher Scientific, founded in the early 20th century, became a leading supplier of laboratory consumables and equipment.

The 2006 merger created an integrated scientific platform combining instrumentation, consumables, and distribution.

In subsequent years, the company expanded through strategic acquisitions that strengthened its capabilities in genomics, molecular biology, and contract pharmaceutical manufacturing. These moves broadened its presence across the full lifecycle of biomedical research and drug production.

In recent years, Thermo Fisher increased investments in bioprocessing capacity, next-generation sequencing, and molecular diagnostics, reinforcing its position as a key supplier to pharmaceutical and biotechnology companies worldwide.

Additional Information

Thermo Fisher Scientific Inc. (United States) is listed on the NYSE and has a market capitalization of $186.54 Billions, with shareholders equity totaling $53.54 Billions.

The company employs approximately 80.000 people and operates in the Health sector, within the Life Science Tools and Services industry.

Over the past 12 months, Thermo Fisher Scientific Inc. reported $44.56 Billions in revenue, generating net income of $6.70 Billions.

Key financial metrics include a P/E ratio of 27.82, a price-to-book (P/B) ratio of 3.48, and a trailing twelve-month dividend yield of 0.35%.

The company trades under the ticker TMO.